Trial · NCT07883031
Effects of Yerba Mate Supplementation on Metabolic Health, Physical Function, and Cognition in Older Adults With Excess Adiposity
NCT07883031, Not applicable, Completed, University of North Alabama
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effects of Yerba Mate Supplementation on Metabolic Health, Physical Function, and Cognition in Older Adults With Excess Adiposity. Trials, record NCT07883031. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07883031
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effects of Yerba Mate Supplementation on Metabolic Health, Physical Function, and Cognition in Older Adults With Excess Adiposity
- NCT number
- NCT07883031
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 25 participants, actual
- Lead sponsor
- University of North Alabama
- Conditions
- Overweight (BMI > 25), Obesity & Overweight
- Interventions
- Yerba Mate, Placebo
- First posted
- 2026-10-20
- Last updated
- 2026-10-20
Source ClinicalTrials.gov
Registered outcomes23
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Fat Oxidation During Walking | Before and after each 6-week supplementation period. | Whole-body fat oxidation rate (g/min), calculated from oxygen uptake and carbon dioxide production measured by indirect calorimetry during standardized treadmill walking. |
| Primary | Walking Economy | Before and after each 6-week supplementation period. | Oxygen cost of walking, expressed in milliliters of oxygen per kilogram of body mass per meter walked. The value is calculated by dividing mass-specific oxygen uptake in mL/kg/min by walking speed in meters per minute. Lower values indicate better walking economy. |
| Primary | Fasting Triglycerides | Before and after each 6-week supplementation period. | Fasting triglyceride concentration (mg/dL), assessed using the Cholestech LDX system. |
| Primary | Psychomotor Vigilance Task Reaction Time | Before and after each 6-week supplementation period. | Reaction time, expressed in milliseconds, during the computerized Psychomotor Vigilance Task, which assesses sustained attention and vigilance. Shorter reaction times indicate faster responses. |
| Primary | Transcript Expression Fold Change | At the end of each 6-week supplementation period. | Expression of protein-coding and noncoding transcripts assessed using the Affymetrix Clariom D human microarray. Differences between yerba mate and placebo supplementation conditions are expressed as fold changes in transcript expression, with results reported individually for each transcript. |
| Primary | Eriksen Flanker Task Incongruent-Trial Reaction Time | Before and after each 6-week supplementation period. | Reaction time, expressed in milliseconds, during incongruent trials of the computerized Eriksen Flanker Task, which assesses inhibitory control. Shorter reaction times indicate faster performance. |
| Primary | Task-Switching Reaction Time | Before and after each 6-week supplementation period. | Reaction time, expressed in milliseconds, during the computerized task-switching task, which assesses cognitive flexibility. Shorter reaction times indicate faster performance. |
| Secondary | Fasting Blood Glucose | Before and after each 6-week supplementation period. | Fasting blood glucose concentration (mg/dL), measured using the Cholestech LDX system. |
| Secondary | Blood Pressure | Before and after each 6-week supplementation period. | Resting diastolic blood pressure (mmHg), measured using an automated upper-arm monitor after 5 minutes of seated rest. |
| Secondary | Interleukin-6 Relative Abundance Fold Change | After each 6-week supplementation period. | Relative plasma interleukin-6 abundance assessed using a cytokine antibody array. Results are expressed as the dimensionless ratio of normalized signal intensity after yerba mate to that after placebo. A ratio of 1 indicates equal abundance between conditions; values above 1 indicate higher abundance after yerba mate, and values below 1 indicate lower abundance compared with placebo. |
1 to 10 of 23Source ClinicalTrials.gov
See all 23 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests3
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Eriksen Flanker Task | Primary outcome | ConductCognition |
| Psychomotor Vigilance Task | Primary outcome | ConductCognition |
| Task Switching Test | Primary outcome | ConductCognition |
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07883031
GET https://conductscience.org/api/trials/v1/NCT07883031/registered?page=2